---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-260679"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2026-06-08T11:15:55+00:00"
generated_at: "2026-06-08T11:20:57.045600+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Tango reports 92% ORR in PDAC with vopimetostat + daraxonrasib combo; plans Phase 3

## Summary
- 92% ORR (11/12) in PDAC with vopimetostat + daraxonrasib; 90% 6-month PFS; 100% DCR.
- 100% ORR (3/3) in NSCLC with same combination; all responses confirmed.
- Vopimetostat + zoldonrasib showed 52% ORR (14/27) in PDAC; 74% 6-month PFS; 96% DCR.
- Combinations well tolerated; no discontinuations due to AEs; no Grade 4/5 related AEs.
- Company plans Phase 3 randomized-controlled trial in front-line pancreatic cancer in 2H 2026.

## SEC filing metadata
- accession: 0001193125-26-260679
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2026-06-08T11:15:55+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000119312526260679/0001193125-26-260679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000119312526260679/d158334d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-260679
- JSON: https://secwatch.observer/filing/0001193125-26-260679.json
- Plain text: https://secwatch.observer/filing/0001193125-26-260679.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.